
Trivalent GalNAc-DBCO

Cat. No.: **SN-M-LM528**

Chemical Properties

Product Name	Trivalent GalNAc-DBCO
Full Name	5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoazatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-4oxobutanoyl]amino]ethoxy]ethoxy]ethoxy]propanoylamino]propoxy]propanoylamino]propyl]pentanediamide
Cat. No.	SN-M-LM528
CAS No.	2765060-22-6
Molecular Formula	C91H144N12O34
Molecular Weight	1950.18
Appearance	Solid
Storage	Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping	Shipping with blue ice/Shipping at ambient temperature.
Solubility	DMSO: 80 mg/mL (41.02 mM), Sonication is recommended.
Purity	98+%

Structure



Biological Description

Trivalent GalNAc-DBCO is a synthetic ligand composed of three GalNAc units linked to DBCO. Trivalent GalNAc-DBCO undergoes strain-promoted alkyne–azide cycloaddition (SPAAC) reactions with azide-containing molecules without the need for copper catalysis. Trivalent GalNAc-DBCO binds specifically to the asialoglycoprotein receptor (ASGPR), thereby directing conjugated molecules into hepatocytes for lysosomal degradation through receptor-mediated endocytosis. Trivalent GalNAc-DBCO is extensively applied in studies of liver-targeted drug delivery, targeted degradation strategies, and hepatocyte-specific molecular engineering.

Related Products / Keywords

- Trivalent GalNAc-DBCO

This product is a research reagent and must not be used for clinical validation or human therapeutic use.